These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38861400)

  • 21. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.
    Ferrieres J; De Ferrari GM; Hermans MP; Elisaf M; Toth PP; Horack M; Brudi P; Lautsch D; Bash LD; Baxter CA; Ashton V; Ambegaonkar B; Gitt AK
    Eur J Prev Cardiol; 2018 Dec; 25(18):1966-1976. PubMed ID: 30335504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome.
    Sobhy M; El Etriby A; El Nashar A; Wajih S; Horack M; Brudi P; Lautsch D; Ambegaonkar B; Vyas A; Gitt AK
    Egypt Heart J; 2018 Sep; 70(3):129-134. PubMed ID: 30190636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study.
    Gavina C; Araújo F; Teixeira C; Ruivo JA; Corte-Real AL; Luz-Duarte L; Canelas-Pais M; Taveira-Gomes T
    Atherosclerosis; 2023 Nov; 384():117148. PubMed ID: 37302923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
    Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
    Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FACTORS INFLUENCING ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS IN MEXICO: THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY.
    Bello-Chavolla OY; Aguilar-Salinas CA
    Rev Invest Clin; 2019; 71(6):408-416. PubMed ID: 31823964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review.
    Bruckert E; Parhofer KG; Gonzalez-Juanatey JR; Nordestgaard B; Arca M; Giovas P; Ray K
    Adv Ther; 2020 May; 37(5):1724-1736. PubMed ID: 32200537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).
    Binbrek AS; Elis A; Al-Zaibag M; Eha J; Keber I; Cuevas AM; Mukherjee S; Miller TR;
    Curr Ther Res Clin Exp; 2006 Jan; 67(1):21-43. PubMed ID: 24936119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions.
    Zhang S; Li ZF; Shi HW; Zhang WJ; Sui YG; Li JJ; Dou KF; Qian J; Wu NQ
    Front Cardiovasc Med; 2022; 9():859567. PubMed ID: 35620524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid management across Europe in the real-world setting: a rapid evidence review.
    Barrios V; Soronen J; Carter AM; Anastassopoulou A
    Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid management and cholesterol goal attainment in Norway.
    Ose L; Skjeldestad FE; Bakken IJ; Levorsen A; Alemao EA; Yin DD; Borgström F; Jönsson L
    Am J Cardiovasc Drugs; 2006; 6(2):121-8. PubMed ID: 16555865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II.
    Liberopoulos E; Rallidis L; Spanoudi F; Xixi E; Gitt A; Horack M; Ashton V; Brudi P; Lautsch D; Ambegaonkar B; Elisaf M
    Arch Med Sci; 2019 Jul; 15(4):821-831. PubMed ID: 31360176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
    Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
    [No Abstract]   [Full Text] [Related]  

  • 38. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL
    Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors.
    Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C
    J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.